Jamali A N, Aqil M, Alam M S, Pillai K K, Kapur P
Department of Pharmacy Practice (Pharmacology), New Delhi - 110 062, India.
J Pharm Bioallied Sci. 2010 Oct;2(4):333-6. doi: 10.4103/0975-7406.72135.
The present study was conducted to monitor adverse drug reactions in patients of bronchial asthma in outpatient department and inpatient department of a university teaching hospital in South Delhi.
About 200 patients irrespective of age and sex with established asthma were interviewed during the time period of January 2006 to April 2006 using structured questionnaire. Naranjo's adverse drug reaction probability scale was used to assess the adverse drug reactions.
A total of 15 adverse drug reactions were reported in 13 out of 200 asthmatic patients. Among the 13 patients reported with adverse drug reactions, 5 (38.5%) were male and 8 (61.5%) patients were female. Maximum percentage of ADRs (2 in 15 prescriptions, 13.3%) observed with montelukast, followed by beclomethasone (1 in 12 prescriptions, 8.3%), salbutamol (6 in 109 prescriptions, 5.5%), and ipratropium (3 in 63 prescriptions, 4.8%).
Montelukast was found to be associated with greater percentage of adverse drug reactions as compared to other antiasthamatics. The above findings are constrained by a small sample size and need to be corroborated by conducting long-term studies using a larger sample size.
本研究旨在监测德里南部一所大学教学医院门诊和住院部支气管哮喘患者的药物不良反应。
在2006年1月至2006年4月期间，使用结构化问卷对约200名确诊哮喘的患者进行了访谈，患者年龄和性别不限。采用纳兰霍药物不良反应概率量表评估药物不良反应。
200名哮喘患者中有13名报告了总共15例药物不良反应。在报告有药物不良反应的13名患者中，男性5名（38.5%），女性8名（61.5%）。观察到孟鲁司特的药物不良反应百分比最高（15张处方中有2例，13.3%），其次是倍氯米松（12张处方中有1例，8.3%）、沙丁胺醇（109张处方中有6例，5.5%）和异丙托溴铵（63张处方中有3例，4.8%）。
与其他抗哮喘药物相比，发现孟鲁司特的药物不良反应百分比更高。上述研究结果受样本量小的限制，需要通过更大样本量的长期研究加以证实。
